JAMES L. ELLIS
Alcoholic Beverages Control in Boxford, MA
License number
Massachusetts SP-LIC-006184
Issued Date
Jan 1, 2016
Expiration Date
Dec 31, 2016
Type
Salesman Permit
Address
Address
Boxford, MA 01921
Organization information
See more information about JAMES L. ELLIS at bizstanding.comPARKER RIVER WINERY INC
21 Pearl Rd, Boxford, MA 01921
Industry:
Whol Wine/Distilled Beverages
Doing business as:
Parker River Winery
Registration:
Jul 30, 2011
Phone:
(978) 317-4084 (Phone)
State ID:
452547002
Business type:
Domestic Profit Corporation
Treasurers:
Guy W. Moxey (President), 26 Baldpate Rd, Boxford, MA 01921 (Physical),James L. Ellis (Treasurer), 21 Pearl Rd, Boxford, MA 01921 (Physical)
Agent:
James P. Bracken,21 Pearl Rd, Boxford, MA 01921 (Physical)
Categories:
Wineries
Professional information
Compounds And Methods For Treatment Of Asthma, Allergy And Inflammatory Disorders
US Patent:
6451801, Sep 17, 2002
Filed:
Mar 24, 2000
Appl. No.:
09/534947
Inventors:
Ralph Scannell - Hopkinson MA
Pierre Chatelain - Pierre, BE
Anna Toy-Palmer - Arlington MA
Edmond Differding - Louvain-La-Neuve, BE
James Ellis - Boxford MA
Marie-Agnes Lassoie - Brainele-Chateau, BE
Xiong Cai - Belmont MA
Sajjat Hussoin - Lexington MA
Gurmit Grewal - Natick MA
Timothy Lewis - Framingham MA
Pierre Chatelain - Pierre, BE
Anna Toy-Palmer - Arlington MA
Edmond Differding - Louvain-La-Neuve, BE
James Ellis - Boxford MA
Marie-Agnes Lassoie - Brainele-Chateau, BE
Xiong Cai - Belmont MA
Sajjat Hussoin - Lexington MA
Gurmit Grewal - Natick MA
Timothy Lewis - Framingham MA
Assignee:
UCB, S.A. - Brussels
International Classification:
A61K 31495
US Classification:
51425303, 5142541, 51425504, 514290, 514318, 514325, 514326, 514331, 544361, 544379, 544380, 544396, 546 93, 546203, 546231, 546234
Abstract:
The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl peperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferable asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.
Analgesic Combination Of Muscarinic Agonists
US Patent:
6828328, Dec 7, 2004
Filed:
Mar 1, 2002
Appl. No.:
10/087283
Inventors:
James Ellis - Boxford MA
Fangming Zou - Wilmington MA
Fangming Zou - Wilmington MA
Assignee:
UCB s.A. - Brussels
International Classification:
A61K 3144
US Classification:
514294, 514282, 514629, 514570, 514406, 514473
Abstract:
This invention relates to the combination of muscarinic agonists with narcotic analgesics, non-steroidal anti-inflammatory drugs or other analgesic drugs and to their use as antinociception (pain relief) agents. In particular, the invention relates to a combination of a specific class of M4 selective muscarinic agonists with narcotic analgesics, non-steroidal anti-inflammatory drugs or other analgesic drugs.
Compounds And Methods For Treatment Of Asthma, Allergy And Inflammatory Disorders
US Patent:
6797713, Sep 28, 2004
Filed:
Sep 12, 2002
Appl. No.:
10/242346
Inventors:
Ralph Scannell - Hopkinson MA
Pierre Chatelain - Woluwe Saint Pierre, BE
Anna Toy-Palmer - Arlington MA
Edmond Differding - Louvain-la-Neuve, BE
James Ellis - Boxford MA
Marie-Agnes Lassoie - Braine-le-Chateau, BE
Michelle Young - Belmont MA
Xiong Cai - Belmont MA
Sajjat Hussoin - Lexington MA
Gurmit Grewal - Natick MA
Timothy Lewis - Marlborough MA
Pierre Chatelain - Woluwe Saint Pierre, BE
Anna Toy-Palmer - Arlington MA
Edmond Differding - Louvain-la-Neuve, BE
James Ellis - Boxford MA
Marie-Agnes Lassoie - Braine-le-Chateau, BE
Michelle Young - Belmont MA
Xiong Cai - Belmont MA
Sajjat Hussoin - Lexington MA
Gurmit Grewal - Natick MA
Timothy Lewis - Marlborough MA
Assignee:
UCB S.A. - Brussels
International Classification:
A61K 31495
US Classification:
51425504, 544396
Abstract:
The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.
Compounds And Methods For Treatment Of Asthma, Allergy And Inflammatory Disorders
US Patent:
6894059, May 17, 2005
Filed:
Mar 23, 2000
Appl. No.:
09/937667
Inventors:
Ralph Scannell - Hopkinson MA, US
Pierre Chatelain - Woluwe Saint Pierre, BE
Anna Toy-Palmer - Arlington MA, US
Edmund Differding - Louvain-La-Neuve, BE
James Ellis - Boxford MA, US
Marie-Agnes Lassoie - Braine-Le-Chateau, BE
Michelle Young - Belmont MA, US
Xiong Cai - Belmont MA, US
Sajjat Hussoin - Lexington MA, US
Gurmit Grewal - Natick MA, US
Timothy Lewis - Framingham MA, US
Pierre Chatelain - Woluwe Saint Pierre, BE
Anna Toy-Palmer - Arlington MA, US
Edmund Differding - Louvain-La-Neuve, BE
James Ellis - Boxford MA, US
Marie-Agnes Lassoie - Braine-Le-Chateau, BE
Michelle Young - Belmont MA, US
Xiong Cai - Belmont MA, US
Sajjat Hussoin - Lexington MA, US
Gurmit Grewal - Natick MA, US
Timothy Lewis - Framingham MA, US
Assignee:
UCB S.A. - Brussels
International Classification:
A61K031/44, A61K031/445
US Classification:
514290, 514325, 514329, 514330, 514331, 514340, 546 93, 546192, 546226, 546229, 5462681
Abstract:
The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obsructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.
Compounds And Methods For Treatment Of Asthma, Allergy And Inflammatory Disorders
US Patent:
2004004, Mar 11, 2004
Filed:
Aug 8, 2003
Appl. No.:
10/637163
Inventors:
Ralph Scannell - Hopkinson MA, US
Pierre Chatelain - Woluwe Saint Pierre, BE
Anna Toy-Palmer - Arlington MA, US
Edmond Differding - Louvain-La-Neuve, BE
James Ellis - Boxford MA, US
Marie-Agnes Lassoie - Braine-Le-Chateau, BE
Michelle Young - Belmont MA, US
Xiong Cai - Belmont MA, US
Sajjat Hussoin - Lexington MA, US
Gurmit Grewal - Natick MA, US
Timothy Lewis - Marlborough MA, US
Pierre Chatelain - Woluwe Saint Pierre, BE
Anna Toy-Palmer - Arlington MA, US
Edmond Differding - Louvain-La-Neuve, BE
James Ellis - Boxford MA, US
Marie-Agnes Lassoie - Braine-Le-Chateau, BE
Michelle Young - Belmont MA, US
Xiong Cai - Belmont MA, US
Sajjat Hussoin - Lexington MA, US
Gurmit Grewal - Natick MA, US
Timothy Lewis - Marlborough MA, US
Assignee:
UCB S.A.
International Classification:
A61K031/496, A61K031/495, A61K031/473, A61K031/4545
US Classification:
514/253010, 514/253030, 514/255040, 514/290000, 514/317000, 514/316000, 544/360000, 544/361000, 546/093000
Abstract:
The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.
Nitrosated And/Or Nitrosylated Compounds, Compositions And Methods Of Use
US Patent:
2009013, May 21, 2009
Filed:
Jan 24, 2005
Appl. No.:
10/586161
Inventors:
James L. Ellis - Boxford MA, US
Assignee:
NitroMed, Inc. - Lexington MA
International Classification:
A61K 31/7048, C07H 19/10, A61P 31/04, A61K 31/7072
US Classification:
514 29, 536 2626, 514 48
Abstract:
The invention describes novel nitrosated and/or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, and at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The nitrosated and/or nitrosylated compounds of the invention are preferably nitrosated and/or nitrosylated antimicrobial compounds, nitrosated and/or nitrosylated adenosine antagonists, nitrosated and/or nitrosylated LTB4 antagonists, nitrosated and/or nitrosylated mucoregulators and nitrosated and/or nitrosylated purine agonists. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis.
Organic Nitric Oxide Donor Salts Of Antimicrobial Compounds, Compositions And Methods Of Use
US Patent:
2009004, Feb 12, 2009
Filed:
Feb 16, 2006
Appl. No.:
11/883445
Inventors:
James L. Ellis - Boxford MA, US
David S. Garvey - Dover MA, US
Chia-En Lin - Concord MA, US
David S. Garvey - Dover MA, US
Chia-En Lin - Concord MA, US
Assignee:
NitroMed, Inc. - Lexington MA
International Classification:
A61K 31/7036, C07H 15/234, C07D 205/085, A61K 31/427, C07D 215/56, A61K 31/4709, C07D 477/00, A61K 31/397, A61P 31/04
US Classification:
514 40, 536 179, 540355, 51421015, 514312, 546156, 540350, 51421012
Abstract:
The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating infections.
Nitric Oxide Enhancing Antimicrobial Compounds, Compositions And Methods Of Use
US Patent:
2009001, Jan 15, 2009
Filed:
Aug 2, 2006
Appl. No.:
11/997536
Inventors:
James L. Ellis - Boxford MA, US
David S. Garvey - Dover MA, US
David S. Garvey - Dover MA, US
Assignee:
NITROMED, INC. - Lexington MA
International Classification:
A61K 31/7036, C07H 15/234, C07D 417/12, A61K 31/397, A61K 31/4375, C07D 471/04, A61K 31/407, C07D 487/04, A61P 31/04, A61P 31/10, A61P 31/12
US Classification:
514 40, 536 179, 51421015, 540355, 546123, 514300, 51421012, 540350
Abstract:
The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating infections.
Sigma Receptor Ligands
US Patent:
2008015, Jun 26, 2008
Filed:
Sep 9, 2005
Appl. No.:
11/574604
Inventors:
James Ellis - Boxford MA, US
Doina Ene - Lisbon CT, US
Eric Schwartz - Wakefield MA, US
Nivedita Namdev - Westford MA, US
Claire Brown - Medford MA, US
David Meyers - Towson MD, US
Doina Ene - Lisbon CT, US
Eric Schwartz - Wakefield MA, US
Nivedita Namdev - Westford MA, US
Claire Brown - Medford MA, US
David Meyers - Towson MD, US
Assignee:
UCB PHARMA, S.A. - Brussels
International Classification:
A61K 31/165, C07C 233/34, A61P 11/14, A61P 25/28, A61P 25/24, A61P 37/00, A61P 29/00
US Classification:
514617, 564161
Abstract:
The present invention concerns phenylcyclopentylacetamides and phenylcyclopropylcarboxamides and analogues thereof, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.